Abstract: A superconducting magnet includes: a superconducting coil; a coolant container; a radiation shield; a vacuum container; a refrigerator configured to cool the inner part of the coolant container and the radiation shield; a first exhaust pipe connected to the coolant container from the outside of the vacuum container and serving as a flow path of the coolant vaporized; a first pressure release valve connected to a distal end of the first exhaust pipe outside the vacuum container and configured to open when a pressure in the coolant container becomes a first set value or higher; a heater provided at the first exhaust pipe and configured to heat the first exhaust pipe; and a detector provided at the first exhaust pipe and configured to detect a change due to occurrence of freezing in the first exhaust pipe.

Abstract: A method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element is disclosed. More specifically, the present application discloses a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.

Abstract: An energy storage device managing apparatus that estimates a degradation amount of a full charge capacity of an energy storage device, the energy storage device managing apparatus includes: a measurement unit that measures a temperature of the energy storage device in a power supply state; a timing unit that measures time in a power non-supply state; and a controller. The controller performs interpolation based on a first temperature measured immediately before the energy storage device becomes the power non-supply state, and a second temperature initially measured after the energy storage device returns to the power supply state, decides a temperature of the energy storage device from a measurement time of the first temperature to a measurement time of the second temperature, and estimates the degradation amount of the full charge capacity based on the decided temperature.

Abstract: Disclosed is a method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element. More specifically disclosed is a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of PSS2. The present inventors have found that PSS1 and PSS2 are in a synthetic lethal relationship, and treatment inhibiting PSS1 serves as a promising approach for the treatment of cancer having the functional suppression of PSS2. It has also been revealed that this therapeutic strategy permits efficient treatment based on companion diagnostics because a PSS1 inhibitor can be administered to a subject selected by using the functional suppression of PSS2 as an index.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: A control device (90) equipped with: switches (91) provided in each charging or discharging current path in each of one or more power storage units (40); a control unit (92) that supplies a control signal to the switch (91); and an external input terminal (83) that supplies an external input signal to the switch (91). Each switch (91) has a function for turning off when the control signal and/or the external input signal is a signal for turning off that switch, or a function for turning on when both the control signal and the external input signal are a signal for turning on that switch.

Abstract: A developing device includes a rotatable developer carrying member enclosing a magnetic field generating portion including a plurality of magnetic poles and configured to carry a developer; and a resinous regulating portion provided at a position opposing the developer carrying member and configured to regulate an amount of the developer carried by the developer carrying member. The regulating portion is formed of a resin material containing magnetic powder, and at least a free end portion, opposed to the developer carrying member, of the regulating portion has relative permeability of 10 or more and 60 or less.

Abstract: A superconducting magnet device with which device breakage caused by a quench can be avoided while helium consumption is reduced. A sheet-like convection-preventing member is disposed at least either above or below a heat transfer member transferring to gaseous helium heat transferred from the outside, so as to cover a helium gas release tube for the gaseous helium, and thus heat exchange performance during transportation is improved. In the case where the quench occurs, the convection-preventing member is lifted upward in the release tube, thereby ensuring to provide a flow path for the gaseous helium and avoiding excessive increase of the internal pressure.

Abstract: A developing device includes a rotatable developer carrying member enclosing a magnetic field generating portion including a plurality of magnetic poles and configured to carry a developer; and a resinous regulating portion provided at a position opposing the developer carrying member and configured to regulate an amount of the developer carried by the developer carrying member. The regulating portion is formed of a resin material containing magnetic powder, and at least a free end portion, opposed to the developer carrying member, of the regulating portion has relative permeability of 10 or more and 60 or less.

Abstract: It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of PSS2. The present inventors have found that PSS1 and PSS2 are in a synthetic lethal relationship, and treatment inhibiting PSS1 serves as a promising approach for the treatment of cancer having the functional suppression of PSS2. It has also been revealed that this therapeutic strategy permits efficient treatment based on companion diagnostics because a PSS1 inhibitor can be administered to a subject selected by using the functional suppression of PSS2 as an index.

Abstract: A superconducting magnet includes: a superconducting coil; a coolant container; a radiation shield; a vacuum container; a refrigerator configured to cool the inner part of the coolant container and the radiation shield; a first exhaust pipe connected to the coolant container from the outside of the vacuum container and serving as a flow path of the coolant vaporized; a first pressure release valve connected to a distal end of the first exhaust pipe outside the vacuum container and configured to open when a pressure in the coolant container becomes a first set value or higher; a heater provided at the first exhaust pipe and configured to heat the first exhaust pipe; and a detector provided at the first exhaust pipe and configured to detect a change due to occurrence of freezing in the first exhaust pipe.

Abstract: A superconducting magnet includes: a superconducting coil; a coolant container; a radiation shield; a vacuum container; a refrigerator; a current lead; a first pipe including a mounting opening in which the refrigerator is inserted and fixed; a second pipe including a lead-out opening through which the current lead passes to be led out; and a flow rate ratio maintaining mechanism connected to at least one of the downstream side of the mounting opening of the first pipe and the downstream side of the lead-out opening of the second pipe, the flow rate ratio maintaining mechanism allowing the vaporized coolant to flow through the first pipe and the second pipe at a constant flow rate ratio.

Abstract: A superconducting magnet includes a superconducting coil, a refrigerant container, a radiation shield, a vacuum container, a refrigerating machine cooling an interior of the refrigerant container, a tubular current lead passing from outside of the vacuum container to inside of the refrigerant container electrically connected to the superconducting coil, a power source electrically connected to the current lead, a manometer measuring a pressure inside of the refrigerant container, a thermometer to measure a temperature of the current lead, and a control unit connected to each of the power source, the manometer, and the thermometer. The control unit raises an output of the power source to vary a value of a current flowing into superconducting coil only when a measurement value of the manometer is higher than or equal to a set value and a measurement value of the thermometer is lower than or equal to a set value.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: A superconducting magnet includes: a superconducting coil; a coolant container; a radiation shield; a vacuum container; a refrigerator; a current lead; a first pipe including a mounting opening in which the refrigerator is inserted and fixed; a second pipe including a lead-out opening through which the current lead passes to be led out; and a flow rate ratio maintaining mechanism connected to at least one of the downstream side of the mounting opening of the first pipe and the downstream side of the lead-out opening of the second pipe, the flow rate ratio maintaining mechanism allowing the vaporized coolant to flow through the first pipe and the second pipe at a constant flow rate ratio.

Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.

Abstract: Problem to be Solved The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenesis effect in in-vivo models.

Abstract: Disclosed is a method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element. More specifically disclosed is a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.